Scientific Sessions
The schedule below reflects the invited program.
Registered attendees: To search a full listing of sessions, view abstracts and plan your schedule for AAIC on your desktop, please use the content portal.
Non-registrants: View and search a full listing of sessions available at AAIC 2014 (abstracts excluded).
PLENARY SESSIONS
SUNDAY, JULY 13: 10:45 - 11:45 a.m.
|
|
Bruno Vellas
*Presented after the Association Welcome Ceremony. |
MONDAY, JULY 14: 10:30 - 11:45 a.m.
|
|
Francine Grodstein
|
|
|
Wiesje Van der Flier
|
TUESDAY, JULY 15: 10:30 - 11:45 a.m.
|
|
Kenneth Langa
|
|
|
Kári Stefánsson
|
WEDNESDAY, JULY 15: 10:45 - 11:45 a.m.
|
|
Rosa Rademakers
|
|
|
Brad Boeve
|
THURSDAY, JULY 17: 10:15 - 11:15 a.m.
|
|
Colin Masters
|
|
|
Randall Bateman
|
SYMPOSIUM SESSIONS
SUNDAY, JULY 13: 8:30 - 10 a.m.
Is It Only Alzheimer's Disease, and Is That Important?
|
Session: S1-01
|
||
|
PRESENTATIONS |
SPEAKERS |
|
|
Pathology Underlying Regional Brain Atrophy (S1-01-01) |
|
Deniz Erten-Lyons
|
|
Hippocampal Sclerosis of Aging (S1-01-02) |
|
Julie Schneider
|
|
Cerebral Amyloid Angiopathy and Alzheimer's Disease (S1-01-03) |
|
Steve Greenberg
|
|
Overlapping Proteinopathies in the Elderly and Their Significance (S1-01-04) |
|
Gabor Kovacs
|
Non-Amyloid Based Therapies
|
Session: S1-02
|
||
|
PRESENTATIONS |
SPEAKERS |
|
|
M1 Muscarinic Agonists and a Multipotent Activator of Sigma1/M1 Muscarinic Receptors: Future Therapeutics of Alzheimer's Disease (S1-02-01 |
|
To be announced. |
|
Lu AE58054, a 5-HT6 Antagonist for Alzheimer's Disease (S1-02-02) |
|
Eskild Colding-Jørgensen
|
|
NACHR7 Agonist for Alzheimer's Disease (S1-02-03) |
|
Gerhard Koenig
|
|
Tau Immunotherapies (S1-02-04) |
|
Einar Sigurdsson
|
MONDAY, JULY 14: 8:30 - 10 a.m.
Long-Term Care: Best Practices for Patients With Dementia
|
Session: S2-01
|
||
|
PRESENTATIONS |
SPEAKERS |
|
|
How to Implement Clinical Research in Nursing Homes? (S2-01-01) |
|
Bob Woods
|
|
What Is Evidence for Effective Long-Term Practices? (S2-01-02) |
|
Lynn Chenoweth
|
|
How to Optimize Care Plans for Patients in Long-Term Care (S2-01-03) |
|
John Morley
|
|
Effective and Ineffective Treatments in Long-Term Care (S2-01-04) |
|
Jiska Cohen-Mansfield
|
Shared Genetic Risks for Neurodegeneration Across Diseases
|
Session: S2-02
|
||
|
PRESENTATIONS |
SPEAKERS |
|
|
Insights into the ALS-FTD Continuum From the Study of C9orf72 (S2-02-01) |
|
Bryan Traynor
|
|
Phagocytosis Pathway of Microglia Linked to Neurodegeneration (S2-02-02) |
|
Harald Neumann
|
|
Lrrk2 and Parkinson's Disease (S2-02-03) |
|
Andrew Singleton
|
|
Mechanisms of Tau Haplotype Effects on Disease (S2-02-04) |
|
Richard Wade-Martins
|
TUESDAY, JULY 15: 8:30 - 10 a.m.
Does Dementia Screening Lead to Overdiagnosis or an Opportunity for Early Intervention?
|
Session: S3-01
|
||
|
PRESENTATIONS |
SPEAKERS |
|
|
Screening for Alzheimer Disease in Cognitively Normal Older Adults: Subjective Cognitive Decline vs Informant Report (S3-01-01) |
|
John Morris
|
|
Screening for Alzheimer's Disease: Why and How? (S3-01-02) |
|
Bruno Dubois
|
|
Early Detection of Dementia and the Principles of Screening (S3-01-03) |
|
Carol Brayne
|
|
Impact of Memory Testing in Different Care Settings in Mislabelling of Dementia (S3-01-04) |
|
Larry Chambers
|
Clinical Trials and Frontotemporal Lobar Dementia (FTLD)
|
Session: S3-02
|
||
|
PRESENTATIONS |
SPEAKERS |
|
|
Convergence of Cell Autonomous and Non-autonomous Stress Systems on Tau Pathogenesis (S3-02-01) |
|
Chad Dickey
|
|
Antisense Oligonucleotides as Therapeutic Agents (S3-02-02) |
|
Tim Miller
|
|
Therapies That Enhance Progranulin Expression (S3-02-03) |
|
Joachim Herz
|
|
Mechanisms of Toxicity and Therapeutic Approaches for c9FTD/ALS (S3-02-04) |
|
Leonard Petrucelli
|
WEDNESDAY, JULY 16: 8:30 - 10 a.m.
Standardization of Biomarkers for Use in Clinical Practice
|
Session: S4-01
|
||
|
PRESENTATIONS |
SPEAKERS |
|
|
Hippocampal Volume (S4-01-01) |
|
Giovanni Frisoni
|
|
Standardization of Amyloid PET: The Centiloid Project (S4-01-02) |
|
William Klunk
|
|
Fluorodeoxyglucose (18F) PET (S4-01-03) |
|
Satoshi Minoshima
|
|
Cerebrospinal Fluid (S4-01-04) |
|
Charlotte Teunissen
|
Role of Immune Response/Microglia in Alzheimer's Disease Risk
|
Session: S4-02
|
||
|
PRESENTATIONS |
SPEAKERS |
|
|
Innate Immunity and Regulation of Abeta (S4-02-01) |
|
Michael Heneka
|
|
Harnessing Innate Immunity to Treat Alzheimer's Disease (S4-02-02) |
|
Terrence Town
|
|
Complement in Alzheimer's Disease: Lessons From C3-Deficient Mice (S4-02-03) |
|
Cynthia Lemere
|
|
Microglial Phenotypes and Aging in Alzheimer's Disease and Other Neurodegenerative Diseases (S4-02-04) |
|
Joseph El Khoury
|
Access 2014 program content
Searchable program content, including session topics, speakers and abstracts, is now available.
